The practical consequence of clinical significance is that some non-APL AML patient may benefit from the ATRA-like therapy, and increased levels of RARA mRNA could be used as a prerequisite for the treatment by SY-1425, which has a power to reset RARα transcriptional activity. The gene discussed is RARA; the disease is acute promyelocytic leukemia.